In a multicenter, randomized, crossover, prospective study, 40 seasonal AR patients were administered both FFNS and MFNS for 2 weeks each in a crossover fashion, for a total of 4 weeks.
Patients completed questionnaires for each product regarding perceived sensory attributes at the end of each two-week period of product administration.
FFNS was significantly preferred over MFNS. Significantly, fewer subjects perceived a bitter taste (p = 0.01), medication running down their throat (p = 0.033), and medication running out of their nose (p = 0.002) with FFNS. MFNS was more frequently reported to induce nasal irritation (p = 0.012), sneezing (p = 0.017), and rhinorrhea (p = 0.007) compared to FFNS. Interestingly, these findings were markedly observed in females. Medicine dripping out of the nose and nasal shooting were the most common problems reported for MFNS with a higher proportion of subjects who felt moderate-to-severe discomfort. Overall, 52.5% of patients expressed a preference for FFNS compared with 22.5% for MFNS.
Several perceived sensory attributes of FFNS were rated significantly superior to MFNS. FFNS may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence.